1
|
Ackley D, Birkebak J, Blumel J, Bourcier T, de Zafra C, Goodwin A, Halpern W, Herzyk D, Kronenberg S, Mauthe R, Shenton J, Shuey D, Wange RL. FDA and industry collaboration: Identifying opportunities to further reduce reliance on nonhuman primates for nonclinical safety evaluations. Regul Toxicol Pharmacol 2023; 138:105327. [PMID: 36586472 DOI: 10.1016/j.yrtph.2022.105327] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2022] [Revised: 12/05/2022] [Accepted: 12/27/2022] [Indexed: 12/29/2022]
Abstract
The nonhuman primate (NHP) has always been a limited resource for pharmaceutical research with ongoing efforts to conserve. This is due to their inherent biological properties, the growth in biotherapeutics and other modalities, and their use in small molecule drug development. The SARS-CoV-2 pandemic has significantly impacted the availability of NHPs due to the immediate need for NHPs to develop COVID-19 vaccines and treatments and the China NHP export ban; thus, accelerating the need to further replace, reduce and refine (3Rs) NHP use. The impact of the NHP shortage on drug development led DruSafe, BioSafe, and the United States (U.S.) Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) to discuss this issue at their 2021 annual meeting. This meeting identified areas to further the 3Rs in NHP use within the current nonclinical safety evaluation regulatory framework and highlighted the need to continue advancing alternative methods towards the aspirational goal to replace use of NHPs in the long term. Alignment across global health authorities is necessary for implementation of approaches that fall outside existing guidelines. This article captures the proceedings from this meeting highlighting current best practices and areas for 3Rs in NHP use.
Collapse
Affiliation(s)
- David Ackley
- Eli Lilly and Co. Inc., Lilly Corporate Center, Indianapolis, IN, 46285, USA
| | - Joanne Birkebak
- Gilead Sciences Inc., 333 Lakeside Dr, Foster City, CA, 94404, USA.
| | - Jorg Blumel
- Genentech Inc., 1 DNA Way, South San Francisco, CA, 94080, USA
| | - Todd Bourcier
- Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, 20993, USA
| | | | - Andrew Goodwin
- Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, 20993, USA
| | - Wendy Halpern
- Genentech Inc., 1 DNA Way, South San Francisco, CA, 94080, USA
| | | | - Sven Kronenberg
- Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center, Basel, Switzerland
| | - Robert Mauthe
- Pfizer Inc., 445 Eastern Point Road, Groton, CT, 06340, USA
| | - Jacintha Shenton
- Amgen Inc., Translational Safety & Bioanalytical Sciences, Thousand Oaks, CA, USA
| | - Dana Shuey
- Incyte Corporation, 1801 Augustine Cut-off, Wilmington, DE, USA
| | - Ronald L Wange
- Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, 20993, USA
| |
Collapse
|
2
|
Brennan FR, Andrews L, Arulanandam AR, Blumel J, Fikes J, Grimaldi C, Lansita J, Loberg LI, MacLachlan T, Milton M, Parker S, Tibbitts J, Wolf J, Allamneni KP. Current strategies in the non-clinical safety assessment of biologics: New targets, new molecules, new challenges. Regul Toxicol Pharmacol 2018; 98:98-107. [PMID: 30026135 DOI: 10.1016/j.yrtph.2018.07.009] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2018] [Accepted: 07/14/2018] [Indexed: 01/07/2023]
Abstract
Nonclinical safety testing of biopharmaceuticals can present significant challenges to human risk assessment with these innovative and often complex drugs. Emerging topics in this field were discussed recently at the 2016 Annual US BioSafe General Membership meeting. The presentations and subsequent discussions from the main sessions are summarized. The topics covered included: (i) specialty biologics (oncolytic virus, gene therapy, and gene editing-based technologies), (ii) the value of non-human primates (NHPs) for safety assessment, (iii) challenges in the safety assessment of immuno-oncology drugs (T cell-dependent bispecifics, checkpoint inhibitors, and costimulatory agonists), (iv) emerging therapeutic approaches and modalities focused on microbiome, oligonucleotide, messenger ribonucleic acid (mRNA) therapeutics, (v) first in human (FIH) dose selection and the minimum anticipated biological effect level (MABEL), (vi) an update on current regulatory guidelines, International Council for Harmonization (ICH) S1, S3a, S5, S9 and S11 and (vii) breakout sessions that focused on bioanalytical and PK/PD challenges with bispecific antibodies, cytokine release in nonclinical studies, determining adversity and NOAEL for biologics, the value of second species for toxicology assessment and what to do if there is no relevant toxicology species.
Collapse
|
3
|
Brorson K, Miesegaes G, Tounekti O, Skene J, Blumel J. Conference summary: gaps, lessons learned, and areas for improvement. PDA J Pharm Sci Technol 2014; 68:83-89. [PMID: 24504238 DOI: 10.5731/pdajpst.2014.00968] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Affiliation(s)
- K Brorson
- Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), Bethesda, MD
| | | | | | | | | |
Collapse
|
5
|
Thomsen H, Reinsch N, Xu N, Looft C, Grupe S, Kuhn C, Brockmann GA, Schwerin M, Leyhe-Horn B, Hiendleder S, Erhardt G, Medjugorac I, Russ I, Forster M, Brenig B, Reinhardt F, Reents R, Blumel J, Averdunk G, Kalm E. Comparison of estimated breeding values, daughter yield deviations and de-regressed proofs within a whole genome scan for QTL. J Anim Breed Genet 2001. [DOI: 10.1046/j.1439-0388.2001.00302.x] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|
6
|
Thomsen H, Reinsch N, Xu N, Looft C, Grupe S, Kuhn C, Brockmann GA, Schwerin M, Leyhe-Horn B, Hiendleder S, Erhardt G, Medjugorac I, Russ I, Forster M, Brenig B, Reinhardt F, Reents R, Blumel J, Averdunk G, Kalm E. A male bovine linkage map for the ADR granddaughter design. J Anim Breed Genet 2000. [DOI: 10.1046/j.1439-0388.2000.00263.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|